These results demonstrated that ANGPTL4 might be an important regulatory factor in the control of decreased MMP-9 expression by suppressing the binding activities of AP-1, Sp-1, and NF-κB​​ in DATS-treated bladder cancer cells. The gene discussed is MMP9; the disease is urinary bladder cancer.